ClinicalTrials.gg
CompletedNCT01926886Updated Sep 18, 2019Results posted

A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

A Phase 3 interventional study of Trastuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
124th of 366
102 · median 61
Started
2013
with 25 others
Phase 3
60 of 374
3 open now
Registered
203rd of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 124th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 203rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm, multicenter study will evaluate the safety of assisted subcutaneous administration of trastuzumab in participants with HER2+ eBC. Participants who have completed the first 6 cycles of intravenous (IV) trastuzumab as part of the (neo)adjuvant treatment will be eligible to receive a further 12 cycles of trastuzumab in this study. Participants will receive IV trastuzumab at initial loading dose of 8 milligrams per kilogram (mg/kg) body weight (BW) for three-weekly (q3w) regimen and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by subcutaneous (SC) administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18).

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed non- primary invasive adenocarcinoma of the breast
  • -positive disease immunohistochemistry (IHC)3+ or in situ hybridization (ISH) positive, in line with local reimbursement criteria and determined in a local laboratory that is experienced/certified in HER2-expression testing using an accurate and validated assay
  • (ECOG) performance status 0-1
  • Hormonal therapy will be allowed as per institutional guidelines
  • (LVEF) of greater than or equal to (>/=) 50% measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC, or, for those who were receiving trastuzumab when beginning the study, documented results within an acceptable limit from a cardiac assessment within 3 months prior to enrollment
  • Participants have completed the first 6 cycles of trastuzumab IV as part of the (neo) treatment
  • No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, (neo-adjuvant or adjuvant)
  • Use of concurrent curative radiotherapy will be permitted

Exclusion criteria

Exclusion Criteria:

  • History of other which could affect compliance with the protocol or interpretation of results. Participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and patients with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible
  • Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
  • Participants with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
  • Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, valvular disease, evidence of transmural infarction on (ECG), diagnosed poorly controlled hypertension
  • Known infection with (HIV), active virus (HBV) or virus (HCV)
  • Pregnant or lactating women
  • Women of and male participants with partners of childbearing potential who are unable or unwilling to use adequate measures during study treatment
  • Concurrent enrollment in another clinical trial using an anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
  • Known to trastuzumab, murine proteins, to any of the of Herceptin including hyaluronidase, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g. difficult to control asthma
  • Inadequate bone marrow, hepatic or renal function
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Trastuzumab

    Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).

    Drug: Trastuzumab

  • No intervention
    Health Care Professionals

    Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.

Interventions

  • Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non- serious AEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An emergent AE was defined as occurring within 35 days after last treatment administration.

    Time frame: Up to 45 months

Secondary outcomes

  1. Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 1 (PSQ1): In-Hospital

    PSQ1 is a quality of care questionnaire containing 14 questions each of Sections A and B, with a total of 28 questions categorized on the opinion of participants about the clinicians, opinion of participants about the other staff and other questions. Responses to questions with section A (except question 11) were categorized to "not at all", "to a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Responses to question 11 with section A were categorized to "Yes, but not long", "yes, quite long", "yes, much long" and "missing". Participant experience with the treatment provided during the in-hospital part of the study was evaluated with PSQ1 questionnaire completed by the participant prior to the first dose of trastuzumab SC at home.

    Time frame: Prior (0 hour) to first trastuzumab SC administration at Cycle 13 (cycle length =21 days)

  2. Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 2 (PSQ2): At Home

    PSQ2 is a quality of care questionnaire containing 13 questions each of Sections A and B, with a total of 26 questions categorized on the opinion of participants about the clinicians, opinion of participant about the other staff and other questions. Responses to questions with section A were categorized to "Not at all", "To a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Participant experience with the treatment provided during the at-home part of the study was evaluated with the PSQ2 questionnaire completed by the participant prior to the fifth dose of trastuzumab SC at home.

    Time frame: Prior (0 hour) to fifth trastuzumab SC administration at Cycle 17 (cycle length=21 days)

  3. Participant-reported Severity of Symptoms as Assessed by Monroe Dunaway Anderson Symptom Inventory (MDASI) Questionnaire

    MDASI questionnaire is used to rate the severity of 13 core items (pain, fatigue, nausea, vomiting, disturbed sleep, distress, shortness of breath, memory difficulties, lack of appetite, drowsiness, dry mouth, sadness, numbness or tingling). Participants were asked to rate the severity of each symptom "at its worst" using 0-10 numerical rating scales with 0 = "not present" and 10 = "as bad as you can imagine." Total score was summed and ranged from 0 to 130, with lower scores indicating better outcome.

    Time frame: Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)

  4. Participant-reported Interference of Symptoms With Life as Assessed by MDASI Questionnaire

    MDASI questionnaire is used to rate the interference of symptoms. The measure includes 6 symptom interference items which ask how much all symptoms, interfere with domains (general activity, mood, work, relations with others, walking, and enjoyment of life). Each items were rated on a 0-10 scale (0 = "did not interfere"; 10 = "interfered completely"). Lower scores indicating better outcome. Total score was summed and ranged from 0 to 50, with lower scores indicating better outcome.

    Time frame: Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)

  5. Number of Participants With Modalities Assessed Using Patient Experience Questionnaires (PEX) - Part 1:In-Hospital

    PEX-Part 1 questionnaire contains 25 items to assess participant's experience on use of trastuzumab at hospital.1.Place of treatment? 2.Was it same place as for chemotherapy? 3.How long did it take to travel there? 4.How easy was travel? 5.Company required for travelling? 6.Was travelling cost a problem? 7.Considering all these,was travelling for treatment overall a problem? 8.How helpful were nursing/medical staff? 9.How pleasant was place of study? 10.How was IV treatment given? 11.If Venous Access Device(VAD),what was it? 12.Did hospital staff have difficulty inserting cannula? 13.Time for cannulation? 14.How painful was IV? 15.How much time to access port/line usually take? 16.How painful was it? 17.Time for IV sessions? 18.Anxiety level while IV treatment? 19.How would you describe IV sessions? 20.Did hospital staff have difficulty giving SC? 21.Time for SC? 22.How painful was SC? 23.Time for SC sessions? 24.Anxiety level while SC treatment? 25.How would you describe SC sessions?

    Time frame: Prior (0 hours) to Cycle 12 (cycle length=21 days)

  6. Number of Participants With Modalities Assessed Using PEX - Part 2: At Home

    PEX - Part 2 questionnaire contains 6 items to assess the participant's experience on the use of trastuzumab SC vials at home.Participants answered the following questions: 1. Did the nursing staff ever have any difficulty giving the trastuzumab injection SC? 2. How many minutes did the injection (it) usually take? 3. How painful was this usually? 4. How long did the SC sessions usually last from arrival until departure of the nurse? 5. How anxious did having the SC treatment make you feel? 6. In general how would you describe these SC treatment sessions at home?

    Time frame: 1 month after end of treatment (up to 10 months)

  7. Number of Health Care Professionals With Modalities Assessed Using Health Care Professional Questionnaire (HCPEX-1)

    HCPEX-1 questionnaire is used to assess health care professional's overall satisfaction and perceived time savings with trastuzumab SC vial in the hospital. The HCPEX-1 questionnaire (19 questions) was completed by the health care professionals administering the trastuzumab IV and SC in the hospital after at least 3 participants had completed the in-hospital part of the study.

    Time frame: Prior (0 hours) to Cycle 12 (cycle length=21 days)

  8. Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria

    DFS was defined as time from first study drug administration (i.e. Day 1 of Cycle 7) to local, regional or distant recurrence, contralateral breast cancer or death from any cause (whichever occurred first). Diagnosis of breast cancer relapse was made based on routine clinical, radiological and laboratory criteria. Acceptable methods of confirmation of recurrence included radiology, computerized tomography (CT) scan, brain scan, ultrasound, or cytology, as per local practice. In case of uncertainly, disease relapse was to be confirmed by histological or cytological examination of a suspicious lesion, if possible.

    Time frame: From start of treatment up to 45 months

07

Results

Posted Sep 18, 2019

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumabHealth Care Professionals
Started10221
Received at least 1 dose of study drug1010
Completed7021
Not completed320
Withdrew: Administrative/other10
Withdrew: Adverse event/intercurrent illness40
Withdrew: Disease progression/recurrence40
Withdrew: Withdrawal by subject150
Withdrew: Failure to return30
Withdrew: Recurrence of disease10
Withdrew: Progression of disease20
Withdrew: Death10
Withdrew: Did not cooperate10

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non- serious AEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An emergent AE was defined as occurring within 35 days after last treatment administration.

Time frame:
Up to 45 months
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsTrastuzumab
Emergent AEs90.1
Emergent SAEs7.9
SecondaryNumber of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 1 (PSQ1): In-Hospital

PSQ1 is a quality of care questionnaire containing 14 questions each of Sections A and B, with a total of 28 questions categorized on the opinion of participants about the clinicians, opinion of participants about the other staff and other questions. Responses to questions with section A (except question 11) were categorized to "not at all", "to a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Responses to question 11 with section A were categorized to "Yes, but not long", "yes, quite long", "yes, much long" and "missing". Participant experience with the treatment provided during the in-hospital part of the study was evaluated with PSQ1 questionnaire completed by the participant prior to the first dose of trastuzumab SC at home.

Time frame:
Prior (0 hour) to first trastuzumab SC administration at Cycle 13 (cycle length =21 days)
Reported as:
Number · participants
Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 1 (PSQ1): In-Hospital
participantsTrastuzumab
1a:Clinician Communication-Not at all0
1a:Clinician Communication-To a small extent4
1a:Clinician Communication-To a moderate extent8
1a:Clinician Communication-To a large extent22
1a:Clinician Communication-To a very large extent49
1a:Clinician Communication-Not applicable0
1a:Clinician Communication-Missing3
1b:Importance-Not important1
1b:Importance-A little important3
1b:Importance-Important19
1b:Importance-Very important40
1b:Importance-Of utmost importance21
1b:Importance-Not applicable0
1b:Importance-Missing2
2a:Confidence in clinicians-Not at all0
2a:Confidence in clinicians-To a small extent0
2a:Confidence in clinicians-To a moderate extent5
2a:Confidence in clinicians-To a large extent23
2a:Confidence in clinicians-To a very large extent56
2a:Confidence in clinicians-Not Applicable0
2a:Confidence in clinicians-Missing2
2b:Importance-Not important0
2b:Importance-A little important1
2b:Importance-Important13
2b:Importance-Very important44
2b:Importance-Of utmost importance25
2b:Importance-Not applicable0
2b:Importance-Missing3
3a:Clinicians cared about you-Not at all2
3a:Clinicians cared about you-To a small extent1
3a:Clinicians cared about you-To a moderate extent6
3a:Clinicians cared about you-To a large extent24
3a:Clinicians cared about you-To very large extent51
3a:Clinicians cared about you-Not applicable0
3a:Clinicians cared about you-Missing2
3b:Importance-Not important0
3b:Importance-A little important2
3b:Importance-Important16
3b:Importance-Very important47
3b:Importance-Of utmost importance18
3b:Importance-Not applicable0
3b:Importance-Missing3
4a:Clinicians interested-Not at all0
4a:Clinicians interested-To a small extent)2
4a:Clinicians interested-To a moderate extent12
4a:Clinicians interested-To a large extent29
4a:Clinicians interested-To a very large extent40
4a:Clinicians interested-Not applicable1
4a:Clinicians interested-Missing2
4b:Importance-Not important0
4b:Importance-A little important2
4b:Importance-Important15
4b:Importance-Very important51
4b:Importance-Of utmost importance15
4b:Importance-Not applicable0
4b:Importance-Missing3
5a:Time with clinicians-Not at all1
5a:Time with clinicians-To small extent4
5a:Time with clinicians-To a moderate extent12
5a:Time with clinicians-To a large extent26
5a:Time with clinician-To a very large extent39
5a:Time with clinicians-Not applicable1
5a:Time with clinicians-Missing3
5b:Importance-Not important0
5b:Importance-A little important2
5b:Importance-Important21
5b:Importance-Very important45
5b:Importance-Of utmost importance14
5b:Importance-Not applicable0
5b:Importance-Missing4
6a:Nurses communication-Not at all0
6a:Nurses communication-To a small extent1
6a:Nurses communication-To a moderate extent4
6a:Nurses communication-To a large extent19
6a:Nurses communication-To a very large extent60
6a:Nurses communication-Not Applicable0
6a:Nurses communication-Missing2
6b:Importance-Not important1
6b:Importance-A little important4
6b:Importance-Important18
6b:Importance-Very important44
6b:Importance-Of utmost importance16
6b:Importance-Not applicable0
6b:Importance-Missing3
7a:Confidence in nurses-Not at all0
7a:Confidence in nurses-To a small extent0
7a:Confidence in nurses-To a moderate extent4
7a:Confidence in nurses-To a large extent19
7a:Confidence in nurses-To a very large extent61
7a:Confidence in nurses-Not Applicable0
7a:Confidence in nurses-Missing2
7b:Importance-Not important0
7b:Importance-A little important1
7b:Importance-Important17
7b:Importance-Very important46
7b:Importance-Of utmost importance19
7b:Importance-Not applicable0
7b:Importance-Missing3
8a:Nurses cared about you-Not at all1
8a:Nurses cared about you-To a small extent2
8a:Nurses cared about you-To a moderate extent4
8a:Nurses cared about you-To a large extent25
8a:Nurses cared about you-To a very large extent52
8a:Nurses cared about you-Not Applicable0
8a:Nurses cared about you-Missing2
8b:Importance-Not important0
8b:Importance-A little important3
8b:Importance-Important22
8b:Importance-Very important41
8b:Importance-Of utmost importance17
8b:Importance-Not applicable0
8b:Importance-Missing3
9a:Nurses interested-Not at all0
9a:Nurses interested-To a small extent3
9a:Nurses interested-To a moderate extent3
9a:Nurses interested-To a large extent22
9a:Nurses interested-To a very large extent56
9a:Nurses interested-Not Applicable0
9a:Nurses interested-Missing2
9b:Importance-Not important0
9b:Importance-A little important5
9b:Importance-Important22
9b:Importance-Very important41
9b:Importance-Of utmost importance14
9b:Importance-Not applicable0
9b:Importance-Missing4
10a:Time with nurses-Not at all0
10a:Time with nurses-To a small extent4
10a:Time with nurses-To a moderate extent10
10a:Time with nurses-To a large extent20
10a:Time with nurses-To a very large extent49
10a:Time with nurses-Not Applicable1
10a:Time with nurses-Missing2
10b:Importance-Not important0
10b:Importance-A little important5
10b:Importance-Important21
10b:Importance-Very important40
10b:Importance-Of utmost importance15
10b:Importance-Not applicable0
10b:Importance-Missing5
11a:Waited for hospital admission-No24
11aWaited for hospital admission-Yes, but not long34
11a:Waited for hospital admission-Yes, quite long20
11a:Waited for hospital admission-Yes, much long4
11a:Waited for hospital admission-Missing4
11b:Importance-Not important5
11b:Importance-A little important12
11b:Importance-Important28
11b:Importance-Very important24
11b:Importance-Of utmost importance12
11b:Importance-Not applicable0
11b:Importance-Missing5
12a:Clinic equipment good order-Not at all0
12a:Clinic equipment good order-To a small extent1
12a:Clinic equipment good order-To moderate extent3
12a:Clinic equipment good order-To a large extent34
12aClinic equipment good order-To very large exten46
12a:Clinic equipment good order-Not applicable0
12a:Clinic equipment in good order-Missing2
12b:Importance-Not important0
12b:Importance-A little important0
12b:Importance-Important22
12b:Importance-Very important41
12b:Importance-Of utmost importance20
12b:Importance-Not applicable0
12b:Importance-Missing3
13a:Clinic otherwise good order-Not at all0
13a:Clinic otherwise good order-To a small extent1
13a:Clinic otherwise good order-To moderate extent5
13a:Clinic otherwise good order-To a large extent32
13aClinic otherwise good order- Very large extent45
13a:Clinic otherwise good order-Not Applicable0
13a:Clinic otherwise good order-Missing3
13b:Importance-Not important0
13b:Importance-A little important2
13b:Importance-Important23
13b:Importance-Very important39
13b:Importance-Of utmost importance18
13b:Importance-Not applicable0
13b:Importance-Missing4
14a:Satisfactory treatment-Not at all0
14a:Satisfactory treatment-To a small extent0
14a:Satisfactory treatment-To a moderate extent1
14a:Satisfactory treatment-To a large extent18
14a:Satisfactory treatment-To a very large extent65
14a:Satisfactory treatment-Not Applicable0
14a:Satisfactory treatment-Missing2
14b:Importance-Not important0
14b:Importance-A little important3
14b:Importance-Important12
14b:Importance-Very important43
14b:Importance-Of utmost importance25
14b:Importance-Not applicable0
14b:Importance-Missing3
SecondaryNumber of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 2 (PSQ2): At Home

PSQ2 is a quality of care questionnaire containing 13 questions each of Sections A and B, with a total of 26 questions categorized on the opinion of participants about the clinicians, opinion of participant about the other staff and other questions. Responses to questions with section A were categorized to "Not at all", "To a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Participant experience with the treatment provided during the at-home part of the study was evaluated with the PSQ2 questionnaire completed by the participant prior to the fifth dose of trastuzumab SC at home.

Time frame:
Prior (0 hour) to fifth trastuzumab SC administration at Cycle 17 (cycle length=21 days)
Reported as:
Number · participants
Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 2 (PSQ2): At Home
participantsTrastuzumab
1a:Clinicians communication-Not at all0
1a:Clinicians communication-To a small extent3
1a:Clinicians communication-To a moderate extent8
1a:Clinicians communication-To a large extent28
1a:Clinicians communication-To a very large extent34
1a:Clinicians communication-Not Applicable7
1a:Clinicians communication-Missing3
1b:Importance-Not important2
1b:Importance-A little important0
1b:Importance-Important20
1b:Importance-Very important37
1b:Importance-Of utmost importance16
1b:Importance-Not applicable0
1b:Importance-Missing8
2a:Confidence in the clinicians-Not at all0
2a:Confidence in the clinicians-To a small extent1
2a:Confidence in the clinicians-To moderate extent2
2a:Confidence in the clinicians-To a large extent20
2a:Confidence in clinician-To very large extent51
2a:Confidence in the clinicians-Not applicable5
2a:Confidence in the clinicians-Missing4
2b:Importance-Not important0
2b:Importance-A little important0
2b:Importance-Important14
2b:Importance-Very important38
2b:Importance-Of utmost importance23
2b:Importance-Not applicable0
2b:Importance-Missing8
3a:Clinicians cared about you-Not at all2
3a:Clinicians cared about you-To a small extent1
3a:Clinicians cared about you-To a moderate extent6
3a:Clinicians cared about you-To a large extent22
3a:Clinician cared about you-To very large extent42
3a:Clinicians cared about you-Not Applicable6
3a:Clinicians cared about you-Missing4
3b:Importance-Not important0
3b:Importance-A little important1
3b:Importance-Important20
3b:Importance-Very important34
3b:Importance-Of utmost importance20
3b:Importance-Not applicable0
3b:Importance-Missing8
4a:Clinicians interested-Not at all0
4a:Clinicians interested-To a small extent1
4a:Clinicians interested-To a moderate extent9
4a:Clinicians interested-To a large extent27
4a:Clinicians interested-To a very large extent36
4a:Clinicians interested-Not applicable6
4a:Clinicians interested-Missing4
4b:Importance-Not important0
4b:Importance-A little important1
4b:Importance-Important19
4b:Importance-Very important34
4b:Importance-Of utmost importance21
4b:Importance-Not applicable0
4b:Importance-Missing8
5a:Clinicians interaction-Not at all1
5a:Clinicians interaction-To a small extent0
5a:Clinicians interaction-To moderate extent11
5a:Clinicians interaction-To a large extent31
5a:Clinicians interaction-To very large extent30
5a:Clinicians interaction-Not Applicable6
5a:Clinicians interaction-Missing4
5b:Importance-Not important0
5b:Importance-A little important0
5b:Importance-Important22
5b:Importance-Very important35
5b:Importance-Of utmost importance18
5b:Importance-Not applicable0
5b:Importance-Missing8
6a:Nurses communication-Not at all0
6a:Nurses communication-To a small extent1
6a:Nurses communication-To a moderate extent1
6a:Nurses communication-To a large extent17
6a:Nurses communication-To a very large extent62
6a:Nurses communication-Not applicable1
6a:Nurses communication-Missing1
6b:Importance-Not important0
6b:Importance-A little important0
6b:Importance-Important22
6b:Importance-Very important39
6b:Importance-Of utmost importance21
6b:Importance-Not applicable0
6b:Importance-Missing1
7a:Confidence in the nurses-Not at all0
7a:Confidence in the nurses-To a small extent0
7a:Confidence in the nurses-To a moderate extent1
7a:Confidence in the nurses-To a large extent23
7a:Confidence in the nurses-To a very large extent58
7a:Confidence in the nurses-Not applicable0
7a:Confidence in the nurses-Missing1
7b:Importance-Not important0
7b:Importance-A little important1
7b:Importance-Important17
7b:Importance-Very important41
7b:Importance-Of utmost importance23
7b:Importance-Not applicable0
7b:Importance-Missing1
8a:Nurses cared about you-Not at all0
8a:Nurses cared about you-To a small extent0
8a:Nurses cared about you-To a moderate extent2
8a:Nurses cared about you-To a large extent23
8a:Nurses cared about you-To a very large extent57
8a:Nurses cared about you-Not applicable0
8a:Nurses cared about you-Missing1
8b:Importance-Not important0
8b:Importance-A little important1
8b:Importance-Important22
8b:Importance-Very important38
8b:Importance-Of utmost importance20
8b:Importance-Not applicable0
8b:Importance-Missing2
9a:Nurses interested-Not at all0
9a:Nurses interested-To a small extent0
9a:Nurses interested-To a moderate extent4
9a:Nurses interested-To a large extent29
9a:Nurses interested-To a very large extent49
9a:Nurses interested-Not applicable0
9a:Nurses interested-Missing1
9b:Importance-Not important0
9b:Importance-A little important2
9b:Importance-Important27
9b:Importance-Very important34
9b:Importance-Of utmost importance18
9b:Importance-Not applicable0
9b:Importance-Missing2
10a:Nurses interaction-Not at all0
10a:Nurses interaction-To a small extent1
10a:Nurses interaction-To a moderate extent6
10a:Nurses interaction-To a large extent26
10a:Nurses interaction-To a very large extent49
10a:Nurses interaction-Not applicable0
10a:Nurses interaction-Missing1
10a:Importance-Not important0
10a:Importance-A little important3
10b:Importance-Important27
10b:Importance-Very important34
10b:Importance-Of utmost importance17
10b:Importance-Not applicable0
10b:Importance-Missing2
11a:Nurses equipment good order-Not at all0
11a:Nurses equipment good order-To a small extent0
11a:Nurses equipment good order-To moderate extent2
11a:Nurses equipment good order-To a large extent27
11a:Nurse equipment good order-To verylarge extent51
11a:Nurses equipment good order-Not applicable1
11a:Nurses equipment good order-Missing2
11b:Importance-Not important1
11b:Importance-A little important2
11b:Importance-Important21
11b:Importance-Very important41
11b:Importance-Of utmost importance17
11b:Importance-Not applicable0
11b:Importance-Missing1
12a:Satisfaction-Not at all0
12a:Satisfaction-To a small extent0
12a:Satisfaction-To a moderate extent0
12a:Satisfaction-To a large extent14
12a:Satisfaction-To a very large extent67
12a:Satisfaction-Not applicable0
12a:Satisfaction-Missing2
12a:Importance-Not important0
12a:Importance-A little important0
12b:Importance-Important18
12b:Importance-Very important42
12b:Importance-Of utmost importance22
12b:Importance-Not applicable0
12b:Importance-Missing1
13a:Care benefit at home-Not at all0
13a:Care benefit at home-To a small extent0
13a:Care benefit at home-To moderate extent0
13a:Care benefit at home-To a large extent18
13a:Care benefit at home-To very large extent63
13a:Care benefit at home-Not applicable0
13a:Care benefit at home-Missing2
13b:Importance-Not important0
13b:Importance-A little important1
13b:Importance-Important19
13b:Importance-Very important41
13b:Importance-Of utmost importance21
13b:Importance-Not applicable0
13b:Importance-Missing1
SecondaryParticipant-reported Severity of Symptoms as Assessed by Monroe Dunaway Anderson Symptom Inventory (MDASI) Questionnaire

MDASI questionnaire is used to rate the severity of 13 core items (pain, fatigue, nausea, vomiting, disturbed sleep, distress, shortness of breath, memory difficulties, lack of appetite, drowsiness, dry mouth, sadness, numbness or tingling). Participants were asked to rate the severity of each symptom "at its worst" using 0-10 numerical rating scales with 0 = "not present" and 10 = "as bad as you can imagine." Total score was summed and ranged from 0 to 130, with lower scores indicating better outcome.

Time frame:
Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)
Reported as:
Mean · units on a scale
Participant-reported Severity of Symptoms as Assessed by Monroe Dunaway Anderson Symptom Inventory (MDASI) Questionnaire
units on a scaleTrastuzumab
Pain- IV (Hospital) - Cycle 71.79 ± 2.51
Fatigue- IV (Hospital) - Cycle 73.76 ± 2.69
Nausea- IV (Hospital) - Cycle 70.82 ± 1.96
Disturbed Sleep- IV (Hospital) - Cycle 73.01 ± 2.89
Distressed- IV (Hospital) - Cycle 71.99 ± 2.27
Breath shortness- IV (Hospital) - Cycle 71.59 ± 2.13
Remembering things-IV (Hospital) - Cycle 71.97 ± 2.32
Lack of appetite-IV (Hospital) - Cycle 70.85 ± 1.80
Drowsy- IV (Hospital) - Cycle 72.25 ± 2.54
Dry mouth- IV (Hospital) - Cycle 71.89 ± 2.51
Feeling sad- IV (Hospital) - Cycle 71.90 ± 2.26
Vomiting- IV (Hospital) - Cycle 70.34 ± 1.31
Numbness- IV (Hospital) - Cycle 73.01 ± 3.20
Pain- SC (Hospital) - Cycle 101.81 ± 2.14
Fatigue- SC (Hospital) - Cycle 103.35 ± 2.45
Nausea- SC (Hospital) - Cycle 100.61 ± 1.41
Disturbed Sleep- SC (Hospital) - Cycle 102.70 ± 2.86
Distressed- SC (Hospital) - Cycle 102.10 ± 2.57
Breath shortness- SC (Hospital) - Cycle 101.29 ± 1.88
Remembering thing- SC (Hospital) - Cycle 102.01 ± 2.21
Lack of appetite- SC (Hospital) - Cycle 100.81 ± 1.67
Drowsy- SC (Hospital) - Cycle 102.32 ± 2.52
Dry mouth- SC (Hospital) - Cycle 101.42 ± 2.06
Feeling sad- SC (Hospital) - Cycle 101.87 ± 2.38
Vomiting- SC (Hospital) - Cycle 100.26 ± 0.81
Numbness- SC (Hospital) - Cycle 102.73 ± 2.76
Pain- SC (Home) - Cycle 131.54 ± 2.33
Fatigue- SC (Home) - Cycle 133.42 ± 2.27
Nausea- SC (Home) - Cycle 130.45 ± 1.25
Disturbed Sleep- SC (Home) - Cycle 132.63 ± 2.50
Distressed- SC (Home) - Cycle 131.81 ± 2.27
Breath shortness- SC (Home) - Cycle 131.28 ± 2.06
Remembering things- SC (Home) - Cycle 131.95 ± 2.07
Lack of appetite- SC (Home) - Cycle 130.43 ± 1.29
Drowsy- SC (Home) - Cycle 131.87 ± 2.26
Dry mouth- SC (Home) - Cycle 131.57 ± 2.30
Feeling sad- SC (Home) - Cycle 131.80 ± 2.32
Vomiting- SC (Home) - Cycle 130.22 ± 1.16
Numbness- SC (Home) - Cycle 132.51 ± 2.64
Pain- SC (Home) - Cycle 161.49 ± 2.06
Fatigue- SC (Home) - Cycle 162.79 ± 2.05
Nausea- SC (Home) - Cycle 160.57 ± 1.35
Disturbed Sleep- SC (Home) - Cycle 162.11 ± 2.28
Distressed- SC (Home) - Cycle 162.01 ± 2.33
Breath shortness- SC (Home) - Cycle 161.38 ± 2.05
Remembering things- SC (Home) - Cycle 162.14 ± 2.12
Lack of appetite- SC (Home) - Cycle 160.71 ± 1.63
Drowsy- SC (Home) - Cycle 161.74 ± 2.01
Dry mouth- SC (Home) - Cycle 161.39 ± 1.93
Feeling sad- SC (Home) - Cycle 161.98 ± 2.24
Vomiting- SC (Home) - Cycle 160.14 ± 0.61
Numbness- SC (Home) - Cycle 162.00 ± 2.29
SecondaryParticipant-reported Interference of Symptoms With Life as Assessed by MDASI Questionnaire

MDASI questionnaire is used to rate the interference of symptoms. The measure includes 6 symptom interference items which ask how much all symptoms, interfere with domains (general activity, mood, work, relations with others, walking, and enjoyment of life). Each items were rated on a 0-10 scale (0 = "did not interfere"; 10 = "interfered completely"). Lower scores indicating better outcome. Total score was summed and ranged from 0 to 50, with lower scores indicating better outcome.

Time frame:
Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)
Reported as:
Mean · units on a scale
Participant-reported Interference of Symptoms With Life as Assessed by MDASI Questionnaire
units on a scaleTrastuzumab
General activity- IV (Hospital) - Cycle 72.77 ± 2.73
Mood- IV (Hospital) - Cycle 72.11 ± 2.13
Work- IV (Hospital) - Cycle 73.22 ± 2.86
Relations- IV (Hospital) - Cycle 71.54 ± 2.13
Walking- IV (Hospital) - Cycle 73.34 ± 3.06
Enjoyment of life- IV (Hospital) - Cycle 72.51 ± 2.55
General activity- SC (Hospital) - Cycle 102.24 ± 2.35
Mood- SC (Hospital) - Cycle 101.92 ± 2.28
Work- SC (Hospital) - Cycle 102.63 ± 2.71
Relations- SC (Hospital) - Cycle 101.48 ± 2.30
Walking- SC (Hospital) - Cycle 102.38 ± 2.69
Enjoyment of life- SC (Hospital) - Cycle 102.21 ± 2.67
General activity- SC (Home) - Cycle 132.27 ± 2.48
Mood- SC (Home) - Cycle 131.81 ± 2.28
Work- SC (Home) - Cycle 132.35 ± 2.26
Relations- SC (Home) - Cycle 131.13 ± 1.93
Walking- SC (Home) - Cycle 132.13 ± 2.79
Enjoyment of life- SC (Home) - Cycle 132.06 ± 2.66
General activity- SC (Home) - Cycle 161.84 ± 2.12
Mood- SC (Home) - Cycle 161.76 ± 2.13
Work- SC (Home) - Cycle 162.00 ± 2.21
Relations- SC (Home) - Cycle 161.02 ± 1.85
Walking- SC (Home) - Cycle 161.67 ± 2.41
Enjoyment of life- SC (Home) - Cycle 161.90 ± 2.37
SecondaryNumber of Participants With Modalities Assessed Using Patient Experience Questionnaires (PEX) - Part 1:In-Hospital

PEX-Part 1 questionnaire contains 25 items to assess participant's experience on use of trastuzumab at hospital.1.Place of treatment? 2.Was it same place as for chemotherapy? 3.How long did it take to travel there? 4.How easy was travel? 5.Company required for travelling? 6.Was travelling cost a problem? 7.Considering all these,was travelling for treatment overall a problem? 8.How helpful were nursing/medical staff? 9.How pleasant was place of study? 10.How was IV treatment given? 11.If Venous Access Device(VAD),what was it? 12.Did hospital staff have difficulty inserting cannula? 13.Time for cannulation? 14.How painful was IV? 15.How much time to access port/line usually take? 16.How painful was it? 17.Time for IV sessions? 18.Anxiety level while IV treatment? 19.How would you describe IV sessions? 20.Did hospital staff have difficulty giving SC? 21.Time for SC? 22.How painful was SC? 23.Time for SC sessions? 24.Anxiety level while SC treatment? 25.How would you describe SC sessions?

Time frame:
Prior (0 hours) to Cycle 12 (cycle length=21 days)
Reported as:
Number · participants
Number of Participants With Modalities Assessed Using Patient Experience Questionnaires (PEX) - Part 1:In-Hospital
participantsTrastuzumab
Place of study treatment: hospital chemo dept87
Place of study treatment: other chemo clinic0
Place of study treatment: Doctor's office0
Place of study treatment: other0
Place of study treatment: missing15
Same place as for your chemotherapy: yes87
Same place as for your chemotherapy: no0
Same place as for your chemotherapy: missing15
Travel time: <1 hour70
Travel time: 1 to 2 hours12
Travel time: >2 hours5
Travel time: missing15
Travelling easy: not at all9
Travelling easy: fairly44
Travelling easy: very34
Travelling easy: missing15
Company required for travelling: always32
Company required for travelling: sometimes19
Company required for travelling: never36
Company required for travelling: missing15
Travelling cost, a problem: not at all60
Travelling cost, a problem: fairly23
Travelling cost, a problem: very4
Travelling cost, a problem: missing15
Travelling overall, a problem: yes18
Travelling overall, a problem: no69
Travelling overall, a problem: missing15
Nursing and medical staff helpful: not at all0
Nursing and medical staff helpful: fairly15
Nursing and medical staff helpful: very72
Nursing and medical staff helpful: missing15
Pleasant place of treatment: not at all3
Pleasant place of treatment: fairly39
Pleasant place of treatment: very44
Pleasant place of treatment: missing16
IV administration method: cannula/needle34
IV administration method:Venous Access Device(VAD)47
IV administration method: both6
IV administration method: missing15
VAD: Hickman0
VAD: peripherally inserted central catheters5
VAD: port-a-cath47
VAD: other9
VAD: missing41
Difficulty inserting the cannula: very often5
Difficulty inserting the cannula: sometimes15
Difficulty inserting the cannula: never22
Difficulty inserting the cannula: missing60
Time for insertion of the cannula: <5 minutes30
Time for insertion of the cannula: 6-10 minutes7
Time for insertion of the cannula: 11-15 minutes1
Time for insertion of the cannula:16-20 minutes0
Time for insertion of the cannula: >20 minutes2
Time for insertion of the cannula: missing62
Cannulation painfull: not at all20
Cannulation painfull: fairly18
Cannulation painfull: very4
Cannulation painfull: missing60
Time for connection to the access port: <5 minutes39
Time for connection to access port: 6-10 minutes8
Time for connection to access port: 11-15 minutes1
Time for connection to access port: 16-20 minutes1
Time for connection to access port: >20 minutes0
Time for connection to access port: missing53
Connection painful: not at all36
Connection painful: fairly14
Connection painful: very0
Connection painful: missing52
Time for IV session: <2 hours21
Time for IV session: 2-3 hours25
Time for IV session: 3-4 hours26
Time for IV session: >4 hours13
Time for IV session: missing17
Anxiety during IV treatment: not at all64
Anxiety during IV treatment: fairly20
Anxiety during IV treatment: very2
Anxiety during IV treatment: missing16
General IV session: very unpleasant2
General IV session: fairly unpleasant15
General IV session: acceptable68
General IV session: missing17
Difficulty in SC injection: very often0
Difficulty in SC injection: sometimes4
Difficulty in SC injection: never82
Difficulty in SC injection: missing16
Time for SC injection: <5 minutes56
Time for SC injection: 6-10 minutes26
Time for SC injection: 11-15 minutes1
Time for SC injection: 16-20 minutes0
Time for SC injection: >20 minutes3
Time for SC injection: missing16
SC injection painful: not at all53
SC injection painful: fairly33
SC injection painful: very1
SC injection painful: missing15
Time for SC session: <2 hours46
Time for SC session: 2-3 hours24
Time for SC session: 3-4 hours9
Time for SC session: >4 hours7
Time for SC session: missing16
Anxiety during SC treatment: not at all63
Anxiety during SC treatment: fairly21
Anxiety during SC treatment: very3
Anxiety during SC treatment: missing15
General SC session: very unpleasant0
General SC session: fairly unpleasant7
General SC session: acceptable79
General SC session: missing16
SecondaryNumber of Participants With Modalities Assessed Using PEX - Part 2: At Home

PEX - Part 2 questionnaire contains 6 items to assess the participant's experience on the use of trastuzumab SC vials at home.Participants answered the following questions: 1. Did the nursing staff ever have any difficulty giving the trastuzumab injection SC? 2. How many minutes did the injection (it) usually take? 3. How painful was this usually? 4. How long did the SC sessions usually last from arrival until departure of the nurse? 5. How anxious did having the SC treatment make you feel? 6. In general how would you describe these SC treatment sessions at home?

Time frame:
1 month after end of treatment (up to 10 months)
Reported as:
Number · participants
Number of Participants With Modalities Assessed Using PEX - Part 2: At Home
participantsTrastuzumab
Difficulty in SC administration: very often0
Difficulty in SC administration: sometimes5
Difficulty in SC administration: never77
Difficulty in SC administration: missing20
SC administration time: <5 minutes65
SC administration time: 6-10 minutes17
SC administration time: 11-15 minutes0
SC administration time: 16-20 minutes0
SC administration time: >20 minutes0
SC administration time: missing20
SC administration Painful: not at all61
SC administration Painful: fairly20
SC administration Painful: very0
SC administration Painful: missing21
Time for SC session: <2 hours82
Time for SC session: 2-3 hours0
Time for SC session: 3-4 hours0
Time for SC session: >4 hours0
Time for SC session: missing20
Anxiety during SC treatment: not at all71
Anxiety during SC treatment: fairly11
Anxiety during SC treatment: very0
Anxiety during SC treatment: missing20
General SC session: very unpleasant3
General SC session: fairly unpleasant0
General SC session: acceptable79
General SC session: missing20
SecondaryNumber of Health Care Professionals With Modalities Assessed Using Health Care Professional Questionnaire (HCPEX-1)

HCPEX-1 questionnaire is used to assess health care professional's overall satisfaction and perceived time savings with trastuzumab SC vial in the hospital. The HCPEX-1 questionnaire (19 questions) was completed by the health care professionals administering the trastuzumab IV and SC in the hospital after at least 3 participants had completed the in-hospital part of the study.

Time frame:
Prior (0 hours) to Cycle 12 (cycle length=21 days)
Reported as:
Number · Health care professionals
Number of Health Care Professionals With Modalities Assessed Using Health Care Professional Questionnaire (HCPEX-1)
Health care professionalsHealth Care Professionals
Specialty: Oncologist0
Specialty: Gynecologist0
Specialty: Oncologist/ Specialist Chemo Nurse19
Specialty: Other2
Specialty: Missing0
Personal administration of SC: always6
Personal administration of SC: sometimes15
Personal administration of SC: never0
Personal administration of SC: missing0
Time required for SC preparation: <5 minutes7
Time required for SC preparation: 6-10 minutes2
Time required for SC preparation: 11-15 minutes1
Time required for SC preparation: 16-20 minutes1
Time required for SC preparation: >20 minutes1
Time required for SC preparation: not sure9
Time required for SC preparation: missing0
Time required for SC administration: <3 minutes1
Time required for SC administration: <5 minutes16
Time required for SC administration: 6-15 minutes3
Time required for SC administration: 16-30 minutes1
Time required for SC administration: 31-60 minutes0
Time required for SC administration: 61-90 minutes0
Time required for SC administration: >90 minutes0
Time required for SC administration: not sure0
Time required for SC administration: missing0
Time for SC session: <2 hours14
Time for SC session: 2-3 hours7
Time for SC session: 3-4 hours0
Time for SC session: >4 hours0
Time for SC session: missing0
Reliability of SC hand held syringe: not at all0
Reliability of SC hand held syringe: fairly10
Reliability of SC hand held syringe: very11
Reliability of SC hand held syringe: missing0
Easy to administer SC hand held syringe:not at all0
Easy to administer SC hand held syringe: fairly13
Easy to administer SC hand held syringe: very8
Easy to administer SC hand held syringe: missing0
convenient method for IV treatment- cannula7
convenient method for IV treatment- VAD14
convenient method for IV treatment- not sure0
convenient method for IV treatment- missing0
Personally administer IV: always4
Personally administer IV: sometimes15
Personally administer IV: never2
Personally administer IV: missing0
Personally Cannulate: always5
Personally Cannulate: sometimes10
Personally Cannulate: never5
Personally Cannulate: missing1
Time for IV preparation: <5 minutes1
Time for IV preparation: 6-10 minutes2
Time for IV preparation: 11-15 minutes2
Time for IV preparation: 16-20 minutes1
Time for IV preparation: >20 minutes5
Time for IV preparation: not sure10
Time for IV preparation: missing0
Time for cannulation: <5 minutes8
Time for cannulation: 6-10 minutes4
Time for cannulation: 11-15 minutes1
Time for cannulation: 16-20 minutes0
Time for cannulation: >20 minutes2
Time for cannulation: not sure5
Time for cannulation: missing1
Time for connection: <3 minutes1
Time for connection: <5 minutes3
Time for connection: 6-15 minutes0
Time for connection: 16-30 minutes2
Time for connection: 31-60 minutes8
Time for connection: 61-90 minutes5
Time for connection: >90 minutes1
Time for connection: not sure1
Time for connection: missing0
Time for IV session: <2 hours5
Time for IV session: 2-3 hours11
Time for IV session: 3-4 hours4
Time for IV session: >4 hours1
Time for IV session: missing0
Anxiety during IV treatment: not at all14
Anxiety during IV treatment: fairly6
Anxiety during IV treatment: very1
Anxiety during IV treatment: missing0
Reliablily of IV treatment: not at all0
Reliablily of IV treatment: fairly8
Reliablily of IV treatment: very13
Reliablily of IV treatment: missing0
IV administration easy: not at all0
IV administration easy: fairly12
IV administration easy: very9
IV administration easy: missing0
Quickest administration: IV0
Quickest administration: SC (handheld syringe)21
Quickest administration: no difference0
Quickest administration: missing0
Require less resource: IV0
Require less resource: SC (handheld syringe)21
Require less resource: no difference0
Require less resource: missing0
SecondaryDisease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria

DFS was defined as time from first study drug administration (i.e. Day 1 of Cycle 7) to local, regional or distant recurrence, contralateral breast cancer or death from any cause (whichever occurred first). Diagnosis of breast cancer relapse was made based on routine clinical, radiological and laboratory criteria. Acceptable methods of confirmation of recurrence included radiology, computerized tomography (CT) scan, brain scan, ultrasound, or cytology, as per local practice. In case of uncertainly, disease relapse was to be confirmed by histological or cytological examination of a suspicious lesion, if possible.

Time frame:
From start of treatment up to 45 months
Reported as:
Median · months
Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria
monthsTrastuzumab
Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory CriteriaNA (NA to NA)

Adverse events

Collected over Up to 45 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab2/101 (2%)8/101 (7.9%)44/101 (43.6%)
Health Care Professionals———
Most frequent serious events
Most frequent serious events
EventTrastuzumabHealth Care Professionals
Ejection fraction decreasedInvestigations5/101—
VertigoEar and labyrinth disorders1/101—
Infected lymphoceleInfections and infestations1/101—
LymphoedemaVascular disorders1/101—
Most frequent other events
Most frequent other events
EventTrastuzumabHealth Care Professionals
FatigueGeneral disorders34/101—
Injection site erythemaGeneral disorders14/101—
Injection site swellingGeneral disorders14/101—

Baseline characteristics

Intent-to-Treat (ITT) population included all enrolled participants. HCPs included for polling purposes. Baseline information not collected on HCPs. HCPs were not enrolled in the study.

Age, Continuous
Age, Continuous(Years)Trastuzumab
Mean54.38 ± 12.28
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab
Female101
Male1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American1
White98
More than one race0
Unknown or Not Reported1
08

Study locations

23 sites
  • Onze Lieve Vrouwziekenhuis Aalst
    Aalst, 9300, Belgium
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • AZ Sint Jan
    Brugge, 8000, Belgium
  • CHU St Pierre (St Pierre)
    Brussels, 1000, Belgium
  • AZ Maria Middelares
    Gent, 9000, Belgium
  • AZ Sint Lucas (Sint Lucas)
    Gent, 9000, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • CH Jolimont - Lobbes (Jolimont)
    Haine-Saint-Paul, 7100, Belgium
  • Clinique Saint-Joseph
    Liège, 4000, Belgium
  • CHU Ambroise Paré
    Mons, 7000, Belgium
  • CHR de Namur
    Namur, 5000, Belgium
  • AZ Damiaan
    Oostende, 8400, Belgium
  • AZ Turnhout Sint Elisabeth
    Turnhout, 2300, Belgium
  • Soroka Medical Center; Oncology Dept
    Beer Sheva, 8410100, Israel
  • Rambam Medical Center; Oncology
    Haifa, 3109601, Israel
  • Hadassah Ein Karem Hospital; Oncology Dept
    Jerusalem, 9112000, Israel
  • Meir Medical Center; Oncology
    Kfar-Saba, 4428164, Israel
  • Western Galilee Hospital; Oncology-Nahariya
    Nahariya, 2210001, Israel
  • Rabin MC; Davidof Center - Oncology Institute
    Petach Tikva, 4941492, Israel
  • Chaim Sheba medical center, Oncology division
    Ramat Gan, 5262000, Israel
  • Kaplan Medical Center; Oncology Inst.
    Rehovot, 7610001, Israel
  • Sourasky / Ichilov Hospital; Dept. of Oncology
    Tel Aviv, 6423906, Israel
  • Assaf Harofeh; Oncology
    Zerifin, 6093000, Israel
09

References and documents

Publications

  • Denys H, Martinez-Mena CL, Martens MT, D'Hondt RG, Graas ML, Evron E, Fried G, Ben-Baruch NE, Vulsteke C, Van Steenberghe MM. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. Breast Cancer Res Treat. 2020 May;181(1):97-105. doi: 10.1007/s10549-020-05604-7. Epub 2020 Apr 2. PubMed 32240454 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Sep 2015, 21 months.

Results were first posted in Sep 2019, 4 years after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 21 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2013
First posted
Aug 21, 2013
StartActual
Nov 19, 2013
Primary completionActual
Sep 4, 2015
CompletionActual
Jul 19, 2017
Results first posted
Sep 18, 2019
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01926886
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 21, 2013
Start date
Nov 19, 2013
Primary completion
Sep 4, 2015
Completion
Jul 19, 2017
Results posted
Sep 18, 2019
Last update
Sep 18, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion